Related Experiment Videos
Hyperlipidemia in renal transplant recipients: natural history and response to treatment
C S Ong1, C A Pollock, R J Caterson
1Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
Insights
Hypercholesterolemia is common after renal transplantation, linked to prednisone and smoking. Simvastatin effectively lowered cholesterol and triglycerides without toxicity in transplant patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hypercholesterolemia is a significant complication following renal transplantation.
- Understanding lipid profile associations and therapeutic responses is crucial for patient management.
Purpose of the Study:
- To assess lipid profiles in renal transplant recipients.
- To identify associations of lipid levels with clinical factors.
- To evaluate the efficacy and safety of simvastatin therapy.
Main Methods:
- Lipid profiles of 192 renal transplant patients were analyzed.
- Associations with immunosuppression (cyclosporin, azathioprine, prednisone), renal function, and lifestyle factors were examined.
- Response to simvastatin therapy was assessed over a mean follow-up of 15.4 months.
Main Results:
- Hypercholesterolemia affected 71.3% of patients within 3 years post-transplant.
- Elevated cholesterol correlated with prednisone dosage, renal function, and smoking.
- Simvastatin significantly reduced serum cholesterol (16.5%) and triglycerides (21%) without toxicity.
- Patients dying from vascular causes had higher cholesterol levels.
Conclusions:
- Hypercholesterolemia is prevalent post-renal transplant and influenced by specific factors.
- Simvastatin is an effective and safe treatment for dyslipidemia in this population.
- Managing lipid profiles is critical for reducing vascular complications in renal transplant recipients.
Abstract:
The lipid profiles of 192 patients with functioning renal transplants and their etiologic associations and response to therapy, in particular simvastatin, were assessed. Hypercholesterolemia was present in 71.3% of patients within 3 years following transplantation. There were independent associations of serum cholesterol with prednisone dosage (p < 0.05), renal function (p < 0.05), and smoking (p < 0.05) in the early posttransplant period (up to 3 months posttransplant). Those patients whose immunosuppression included cyclosporin had lower serum cholesterol levels than those receiving azathioprine and prednisone (p < 0.02). Plasma triglyceride levels reflected a marked interindividual variation, and no independent correlations were observed. The presence of diabetes mellitus, hypertension (or the use of antihypertensive agents), or the form or duration of prior dialysis did not independently influence the lipid profiles. During the study period 22 patients died, 54.5% due to vascular causes. Those who died of vascular causes had higher serum cholesterol levels than those who died of other causes, which reached statistical significance at 3 years posttransplant (7.74 +/- 0.4 versus 5.5 +/- 0.52 mmol/L; p < 0.02). Cholestyramine was introduced in 30 patients, only 2 of whom continued with therapy beyond 3 months. Simvastatin was used in 43 patients, 20 of whom were receiving cyclosporin, resulting in a mean reduction in serum cholesterol of 16.5% (p < 0.001) and in serum triglycerides of 21% (p < 0.05). No clinical or biochemical evidence of muscle, liver, or renal toxicity occurred in 15.4 +/- 0.9 months of follow-up.